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Introduction
There is no population based tumour registry in most of
the developing countries and Pakistan is no exception to
it. The annual incidence of cancer, therefore, remains
unknown. The reported annual incidence of Acute
Lymphoblastic Leukaemia (ALL) from other countries is
almost 30-40 per million children below the age of 18
years.1 This is the most common malignancy of
childhood1-3 representing almost a quarter of all cancers
diagnosed in this age group. The peak incidence is in
children aged between 2 and 5 years. In the US, each year
2000-2500 new cases of childhood ALL are diagnosed.
Internationally and in Pakistan as well, the incidence is
thought to be similar. Children treated on current
chemotherapy protocols have an event-free survival (EFS)
that exceeds 85%. This success is mainly due to treatment
stratification according to the risk of relapse and provision
of better supportive care.4
The incidence of ALL is higher among boys than in girls;5
the difference being the greatest among pubertal
children. In earlier studies, male gender was a distinctly
poor prognostic factor.6 Some of the inferior outcome in
boys were related to the higher percentage of poor
prognostic features.6 These children generally present
with signs of bone marrow failure, including anaemia,
thrombocytopenia and neutropenia with clinical
manifestations of fatigue, pallour, bleeding and fever.6
A proportion of these patients maintain sustained
remission which allowe investigators to define sub-group
with a higher or lower risk for relapse.6,7 The National
Cancer Institute NCI criteria divide patients into standard
and high-risk categories. Children between 1 and 9 years
of age with a white blood cell (WBC) count at presentation
of <50X109/L fall into the standard risk category. Children
older than 10 years or of any age with an initial WBC count
of >50 X 109/L are categorised as high-risk. Other factors
that have an influence on the outcome of treatment
include certain cytogenetic or molecular changes in
leukaemia cells. The presence of central nervous system
(CNS) or testicular disease at presentation also puts a child
at a higher risk of relapse.8-12
The understanding of the biological features of childhood
leukaemia has increased over the past decade.12-14 The
ability to discern genetic differences among
morphologically and immunologically similar populations
of leukaemic cells has helped to establish the basis for a
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Abstract
Objective: To evaluate the demographic features, outcome and prognostic factors seen in children with acute
lymphoplastic leukaemia at a tertiary care hospital.
Methods: The retrospective descriptive study was conducted at Aga Khan University Hospital, Karachi, comprising
data related to children below 15 years of age and treated between January 1997 and December 2006. Kaplan Meir
survival curves were used to describe overall and event-free survival rates. Cox Proportional Hazards model was
used to describe factors associated with death and relapse. SPSS 16 was the main statistical tool.
Results: Of the total 121 children diagnosed with the condition, 79 (65.3%) were males; 86 (71.1%) patients were
between 1-9 years of age; Immunophenotyping was done in 99 (81.81%) patients: 86 (87%) cases had precursor B and
13 (13.13%) had precursor T. Of the total, 106(87.6%) patients opted for treatment, while 15 (11.6%) were lost to
follow-up. Besides, 26(21.7%) patients had at least one relapse; the most common site being bone marrow in 13 (50%)
followed by central nervous system in 9 (36.6%). There were 20(16.5%) deaths in the sample. Infection was the most
frequent cause of death. The event-free survival and overall survival was 63% (n=76) and 65%(n=79) respectively.
Conclusion: Through the clinical characteristics of children with acute lymphoblastic leukamia were similar to those
reported in literature, the outcomes were inferior. The high rate of infections and relapse warrant better supportive
care and risk-based approach.
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revised classification of leukaemia. This advance, in turn,
has pointed the way towards new approaches to clinical
management. 
Very little is known about the demographics and outcome
of children with ALL in Pakistan. The study was aimed at
identifying the clinical features, laboratory markers and
the outcome of children diagnosed and treated with ALL.
This would help clarify if these variables were different
from those reported elsewhere and would determine
some of the prognostic factors. Though a single-centre
study, this will serve as a platform for future studies and
facilitate in improving the treatment outcomes.
Patients and Method
The retrospective descriptive study was conducted at the
Aga Khan University Hospital, Karachi. Data of all children
<15 years of age who were newly diagnosed to have ALL
between January 1997 and December 2006 was eligible.
Children who presented with relapse or who were
diagnosed elsewhere were not included. The data,
including age, gender, clinical features at presentation
(pallor, fever, bruises, weight-loss, nausea, vomiting,
testicular swelling, headache, hepatomegaly, bone pains)
and laboratory data, including initial WBC count, bone
marrow and immunophenotyping results, cerebrospinal
fluid (CSF) analysis, number and type of relapses, were
retrieved by retrospective chart analysis from the Medical
Record Department, which uses International
Classification of Disease version 9 databases (ICD 9.0). A
proforma was structured for the purpose.
The treatment protocol was based on the BFM (Berlin-
Frankfurt-Munich) backbone. Induction phase over 4
weeks included 4 drugs namely vincristine 1.5gm/m2
weekly, oral prednisolone 60mg/m2 daily, L-asparaginase
2500 IU/m2 (9 doses) and daunomycin 25mg/m2 weekly
with intrathecal methotrexate on day 1, 15 and 28. This
was followed by consolidation over 4 weeks with
cyclophosphamide 1000mg/m2 day 1 and 14, cytosine
arabinoside 75mg/m2 for 4 days every week and oral 6MP
daily with weekly intrathecal methotrexate. Interim
maintenance of 2 months consisted of methotrexate
75mg/m2 every two weeks and oral 6MP daily. Delayed
intensification over 2 months consisted of vincristine 1.5
mg/m2 weekly for 4 weeks, adriamycin 25mg/m2 weekly
for 4 weeks, dexamethasone 10mg/m2 daily for 4 weeks,
cyclophosphamide 1000mg/m2 on day 35, cytosine
arabinoside 75mg/m2 4 times per week for 2 weeks
starting day 36 and intrathecal methotrexate day 39 and
46. The maintenance therapy included daily oral 6-
mercaptopurine, weekly doses of oral methotrexate and 4
weekly pulses of vincristine with prednisolone with
intrathecal methotrexate every 3 months. Prophylactic
CNS radiation was given only to children with T-ALL (1200
Gy), whereas all patients (both B- and T-cell) with overt
CNS disease received radiation therapy in a dose of 1800
Gy. The total duration of therapy was 30 months for girls
and 36 months for boys.
The data was analysed using SPSS version 16.0. For
categorical data frequencies along with percentages
were calculated. For continuous variables with a skewed
distribution, median with Inter Quartile Range (IQR) were
described. To account for censoring and lost to follow-up,
Kaplan Meir survival curves were used to describe overall
and event-free survival rates. A univariate Cox
proportional hazards regression model was employed for
deaths and relapses as the event and time to death and
relapse as the time variable. . Cases with missing values
were dropped from further analysis. Hazard Ratios (HR)
along with 95% confidence (CI) were calculated to
identify variables associated with an increased risk of
death or relapse.15
Results
Patient characteristics were identified at the time of
diagnosis (Table-1). A total of 121 ALL patients were
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Table-1: Patient Characteristics.
Variables n Percentage
Overall 121
Gender
Male 79 65.3
Female 42 34.7
Age 
<1 year 8 6.6
1.0 – 9.9 years 86 71.1
>10 years 27 22.3
Fever 98 81%
Pallor 100 82.6
Bruises 56 46.3
Weight-loss 52 43
Nausea/Vomiting 20 16.5
Hepatomegaly 78 64.5
Testicular swelling 2 1.7
Bone pains 26 21.5
Precursor B – cell Immunophenotype 86* 87
T-cell immunophenotype 13* 13
Risk category^
High Risk 46 38
Standard Risk 75 54.5
WBC
<50X109/L 106 87.5
>50X109/L 15 12.5
*Out 99. ^Risk category - High risk defined as WBC >50,000 and/or age >9.99yrs at diagnosis.
Standard risk defined as WBC<50,000 and/or age <9.99yrs at diagnosis. WBC: White blood cells.
diagnosed during the study period. Of them, 15(11.6%)
patients were lost to follow-up. 
The majority of patients (n=86; 71%) were between 1.0 =
9.9 years of age, followed by 27 (22%) who were >10 years
old and only 8(6%) were below one year of age. There
were 79 (65.3%) males and 42 (34.7%) females. Fever
(n=98; 81%) and pallor (n=100; 82.6%) were the most
common presentation' followed by weight-loss in 52
(43%) patients. Two (1.7%) patients presented with
testicular swelling. Besides, 106 (87.5%) children had a
WBC count of <50X109/L, while 15(12.5%) had >50X109/L.
Overt CNS symptoms were documented in 11 (9.1%)
cases. All these patients complained of headache at
presentation, while two (1.7%) had seizures and one
(0.8%) presented with paraplegia. Eight (72.72%) patients
in this sub-group were male. The cerebrospinal fluid
contained >5 blasts/cmm in all the 11 patients. 
Immunophenotyping results at diagnosis were available
for 99 (81.81%) patients. Of them, 86 (87%) cases were
classified as having Precursor-B ALL and 13 (13%) as T-ALL.
Day 28 bone marrow results were available for 96(79.33%)
patients; out of whom remission (M1 marrow status) was
attained in 93 (97%). 
Twenty-six (21.5%) patients had a relapse. Median time to
relapse was 14.6 months from diagnosis. Out of these 26
patients, immunophenotyping results from initial
diagnosis were available in 21 (80.76%) patients; 15 (71%)
had Precursor- B ALL, while 6 (28.5%) had T- ALL. All of the
6 patients with T-ALL relapsed as CNS disease. Site of
relapse was bone marrow in 13 (50%), CNS in 9 (30%),
testes in 3 (11%) and combined in 1 (4%) of the patients.
All of them were treated as per BFM relapse ALL protocol.
Three (14.3%) children died during treatment because of
progressive disease. 
There were 21 (17%) deaths; 9 (45%) during the induction
phase (induction death rate of 8.5%), 3 (15%) during the
consolidation phase, and 8 (40%) during the maintenance
phase of chemotherapy. The most common cause of
death was infection in 15 (71.4%), progressive disease in 3
(14.3%) and haemorrhage in 3 (14.3%) patients.
Given a median follow-up of 28 months (IQR 8-43), the
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Figure-1: Overall survival.
overall survival(OS) and event-free survival (EFS) were
65%(n=76) and 63%(n=79) respectively, (Figures-1 and 2).
Cox proportional hazard model (Table-2) showed that
only WBC count had a statistically significant association
with relapse or death. The rate of death or relapse in those
patients who had a WBC count >50 x 109 /L was 2.7 times
the rate of relapse or death in patients with WBC count
<50 x 109/L throughout the study period. Hazard ratios as
low as 1.28 and as high as 5.71 were observed at 95% level
of confidence.
Discussion
The exact incidence of childhood cancer in Pakistan is not
known because of the non-existence of a population-
based tumour registry. There has been an attempt to
develop a tumour registry for one district of Karachi.
According to this registry, the incidence of childhood
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Table-2: Cox proportional hazard model presentation.
Variables Hazard Ratio (HR) with 95% CI15
Age
<1 year
1.0- 9.9 years 0.42(0.12-1.4)
>10 years 0.75(0.21-2.7)
Gender
Male
Female 1.2(0.64-2.31)
WBC Count 
<50x109/L
>50x109/L 2.71(1.28-5.71)
Final Diagnosis
Pre B ALL
T cell ALL 1.36(0.57-3.23)
ALL: Acute Lymphoplastic Leukaemia. WBC: White blood cells. CI: confidence interval.
Figure-2: Event-free survival.
cancer is 9/100,000.16 Extrapolating the registry for the
whole country, approximately 8000-9000 new cases of
cancer, and 3000 new cases of leukaemia occur in children
each year.16 Of this, only half reach a facility where
treatment is available. Even there, the survival is not more
than 50%, making the OS not more than 25-30%.1 Reason
for this is inaccessibility to tertiary care centres with
paediatric cancer units, poverty, lack of knowledge and
awareness among our general practitioners, and illiteracy.
In our study, 15 patients were lost to follow-up. Higher
rates of abandonment have been reported from China
and neighbouring countries.17,18
Studies from Asia have reported that over half of the cases
could be categorised as high-risk, based on age, WBC
counts on presentation, presence of CNS disease at
diagnosis and male gender.17 In contrast high-risk disease
is encountered in only 10% of the cases in developed
nations.19-21 In our cohort of patients, almost 40% were in
the high-risk group based on age, initial WBC count,
CNS/testicular disease and T-ALL phenotype. This is
consistent with the data from other resource-poor
countries.23-25 This difference may be because of late
referrals but inherently different biology of leukaemia
cells needs to be investigated. In contrast to the reported
equal incidence of disease in males and females from the
developed nations,26,27 we observed a definite bias
towards the male gender. This probably reflects the
neglect of the female child in our society. High WBC count
at presentation was documented in 15 (12.5%) of our
patients. Investigators from Europe and USA have also
observed hyperleucocytosis in 10-15% of the patients.26
These patients are at higher risk for developing tumour
lysis syndrome and other complications needing
aggressive supportive management.
Relapse was documented in 26 (21.5%) cases, which is
higher in comparison to figures from the developed
countries.28 Relapse of disease while on chemotherapy
and high incidence of CNS relapse indicates the need to
re-evaluate our treatment protocols especially for T-ALL.
The high incidence of CNS relapse re-emphasises the
need for the use of intravenous high-dose methotrexate,
especially in high-risk patients, including T-ALL.
The age and the WBC count on presentation have been
shown to have significant impact on the outcome of
childhood ALL. The NCI devised criteria of putting
children to the standard risk group where the age is
between 1 and 10 years and the WBC count less than 50 x
109/L, whereas children of age 10 years or above with any
WBC count or of any age with WBC count of >50x109/L to
the high risk group. We also found WBC count >50x109/L
at any age, associated with a less favourable outcome in
univariate analysis. Most of the Asian and USA-based
studies have also shown the same results.10 Investigators
in Chile, South Africa and USA have also identified age as
an important prognostic factor.22,23 Although the data is
retrospective and from a single institute, but the
estimated OS and EFS in our study is inferior compared to
the more developed countries, but it still fares better than
some of the other South East Asian countries,25 and the
only other study so far published from Pakistan. 
The contributing factors for low EFS and OS have
previously been reported to be associated with the higher
numbers of toxic deaths, increased relapse rate, poor
nutritional status, poor socioeconomic conditions, delay
in diagnosis and lack of approach to a tertiary care unit.28
High rates of toxic deaths related to infections during
induction as well as maintenance warrants better
supportive care, more aggressive approach to manage
febrile neutropenia and risk adapted less intense (three
drugs) induction therapy for standard risk patients.
Though recently there has been limited availability of
facilities to conduct cytogenetic and molecular studies for
better risk assessment for appropriate therapy, these
needs to be more generally available. There should be
more multi-centre studies to identify other risk factors
behind poor outcomes. 
Conclusion
There is a strong need to educate the paediatricians and
family physicians to be able to suspect childhood
leukaemia and early referral to appropriate centres.
There is a need to increase the awareness of general
public regarding childhood malignancies. The general
belief of cancer being incurable should be addressed
and information about excellent outcome in majority of
the children diagnosed with leukaemia be propagated
at a large scale.
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